La jolla pharmaceutical company (LJPC)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Revenue
Net product sales

23,054

10,056

0

0

-

-

-

-

-

-

Contract revenue - related party

-

-

0

616

1,057

0

0

-

-

-

Total revenue

23,054

10,056

0

616

1,057

0

0

-

-

-

Operating expenses
Cost of product sales

2,392

1,643

0

0

-

-

-

-

-

-

Research and development

85,329

117,302

84,575

62,288

29,092

9,944

4,362

1,353

177

13

Selling, general and administrative

45,134

85,162

30,852

16,700

-

-

-

-

-

-

Selling, general and administrative

-

-

-

-

13,934

11,396

13,579

9,386

2,097

3,915

Total operating expenses

132,855

204,107

115,427

78,988

43,026

21,340

17,941

10,739

2,274

3,928

Loss from operations

-109,801

-194,051

-115,427

-78,372

-41,969

-21,340

-17,941

-10,739

-2,274

-3,928

Interest expense

10,774

7,303

-

-

-

-

-

-

-

-

Interest expense

-

-

0

0

-

-

-

-

-

-

Interest income

2,128

1,885

624

187

-

-

-

-

-

-

Other income—related party

1,939

0

-

-

-

-

-

-

-

-

Total other income (expense), net

-6,707

-5,418

-

-

-

-

-

-

-

-

Adjustments to fair value of derivative liabilities

-

-

-

-

-

-

-

2,998

-

-

Fair value of derivative liabilities in excess of proceeds

-

-

-

-

-

-

-

-

-

-5,015

Adjustments to fair value of derivative liabilities

-

-

-

-

-

-

-

-

-9,508

5,347

Financing transaction costs

-

-

-

-

-

-

-

-

-

163

Interest income

-

-

624

187

57

27

6

4

234

-1

Net loss

-116,508

-199,469

-114,803

-78,185

-41,912

-21,313

-17,935

-7,737

-11,548

-3,760

Convertible preferred stock dividends earned

-

-

-

-

-

-

801

780

119

466

Net loss attributable to common shareholders

-

-

-

-

-41,912

-21,313

-18,736

-8,517

-11,667

-4,226

Net loss per share, basic and diluted (usd per share)

-4.30

-7.85

-5.41

-4.54

-2.68

-2.00

-12.16

-41.77

-31.59

-5.00

Weighted-average common shares outstanding - basic and diluted (in shares)

27,112

25,422

21,215

17,228

15,651

10,667

1,540

203,924

369

-